AFS and Trading Securities - Unrealized Loss Position (>=12 Months)
Medtronic AFS and Trading Securities - Unrealized Loss Position (>=12 Months) increased by 38.9% to $1.90B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 42.6%, from $3.30B to $1.90B. Over 4 years (FY 2021 to FY 2025), AFS and Trading Securities - Unrealized Loss Position (>=12 Months) shows a downward trend with a -9.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
A high or increasing value suggests potential long-term credit risk or persistent valuation challenges in the portfolio.
Detailed definition
The fair value of debt securities classified as available-for-sale or trading that have been in an unrealized loss posit...
Peer comparison
Used by analysts to evaluate the quality and long-term health of an insurer's investment portfolio.
afs_debt_securities_unrealized_loss_12m_plusHistorical Data
| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.42B | $3.95B | $5.48B | $2.86B | $5.00B | $5.07B | $5.13B | $4.81B | $4.76B | $4.79B | $4.74B | $3.95B | $4.30B | $3.27B | $3.14B | $3.30B | $2.99B | $2.43B | $1.36B | $1.90B |
| QoQ Change | — | -10.6% | +38.5% | -47.8% | +75.1% | +1.4% | +1.1% | -6.3% | -1.0% | +0.5% | -1.0% | -16.7% | +8.8% | -23.8% | -4.1% | +5.2% | -9.3% | -18.7% | -43.9% | +38.9% |
| YoY Change | — | — | — | — | +13.1% | +28.3% | -6.3% | +68.2% | -4.9% | -5.6% | -7.6% | -17.9% | -9.7% | -31.6% | -33.8% | -16.4% | -30.3% | -25.6% | -56.5% | -42.6% |
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) at Other Companies
Frequently Asked Questions
- What is Medtronic's afs and trading securities - unrealized loss position (>=12 months)?
- Medtronic (MDT) reported afs and trading securities - unrealized loss position (>=12 months) of $1.90B in Q4 2025.
- How has Medtronic's afs and trading securities - unrealized loss position (>=12 months) changed year-over-year?
- Medtronic's afs and trading securities - unrealized loss position (>=12 months) decreased by 42.6% year-over-year, from $3.30B to $1.90B.
- What is the long-term trend for Medtronic's afs and trading securities - unrealized loss position (>=12 months)?
- Over 4 years (2021 to 2025), Medtronic's afs and trading securities - unrealized loss position (>=12 months) has grown at a -9.3% compound annual growth rate (CAGR), from $4.42B to $2.99B.
- What does afs and trading securities - unrealized loss position (>=12 months) mean?
- The current market value of debt investments that have been worth less than their cost for a year or more.